Microbiome Connect : Gut Therapeutics 2021

Microbiome Connect: Where innovation meets industry

Highlighting the Latest Clinical Research and Innovation in the Gut Microbiome Therapeutics Field

Tickets On Sale Now
COURTYARD BY MARRIOTT, BOSTON DOWNTOWN BOUTIQUE HOTEL
17-18 November, 2021

“This event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science. Kisaco has gone out of their way to include speakers and perspectives not found elsewhere. I look forward to attending again.”

KC Microbiome Communications Group

Why Attend

Clinical data continues to implicate the gut microbiome in an array of indications, evidencing the vast potential as a future drug target and source of biomarkers.

We are approaching a pivotal time in the industry's development. The global human microbiome therapeutics market is forecasted to be worth $ 1,544 million by 2027! With 27% of microbiome drugs are entering phase 2 trials. It is time to cement your foundations to ready yourself for the incoming market boom.

Microbiome Connect: Gut Therapeutics will bring you essential solutions to the array of challenges operating in the microbiome field. The event will facilitate your discussions, uniting academics, biotechs and other industry stakeholders to share their exclusive research and innovation. Hear from big pharma to understand what they look for in a partner.

Join us for two full days of innovation, discussion, and networking opportunities to further develop your knowledge and business opportunities in the gut microbiome therapeutics field.

Microbiome Connect: Where innovation meets industry.

200+
Attendees
50+
Leading Top Speakers
10+
Hours of Dedicated Networking

What's new for 2021

1. A dedicated manufacturing stream.

Witness a showcase of solutions to scaling up your bacterial fermentation operation, highlighting the different culturing methodologies, along with discussions regarding commercialisation preparation!

2. Join the microbiome biomarker conversation.

We will hear from companies like Takeda, Merck, and the PRI to discuss the clinical future of the microbiome as a diagnostic and endpoint, as well as examining how the industry can and should develop standardised biomarkers.

3. From clinical to conference!

Find leading biotech’s, discussing their latest clinical updates, mechanistic data, experimental methods, and clinical trial design.

Who Will Be There

20%
Academics
50%
Biotech
10%
Pharma
20%
CDMO, CRO and Bioinformatics Companies

Academics

Biotech

Pharma

CDMO, CRO and Bioinformatics Companies

Agenda

Please fill in your details to download the 2021 agenda. 

Microbiome Connect Gut Therapeutics Boston 2021 Kisaco Research

Download our Agenda

2021 Speakers

 

Peter Marks

Director
FDA

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development.  He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Peter Marks

Director
FDA

Peter Marks

Director
FDA

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development.  He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

 

Julius Goepp

CEO
Scaled Microbiomics

Julius Goepp

CEO
Scaled Microbiomics

Julius Goepp

CEO
Scaled Microbiomics
 

Nikole Kimes

Founder and CSO
Siolta Therapeutics

Talk to me about… your research

Nikole Kimes

Founder and CSO
Siolta Therapeutics

Nikole Kimes

Founder and CSO
Siolta Therapeutics

Talk to me about… your research

Our mission at Siolta Therapeutics is to transform the therapeutic landscape of inflammatory diseases, such as asthma, through the power of the microbiome. As the lead executive driving Siolta’s early-stage development, I head a talented team of scientists, blending microbiology, immunology, and bioinformatics expertise to leverage microbiome data for the improvement of patient stratification and development of targeted microbial therapeutics. We are developing FDA-approved live biotherapeutics, as well as companion diagnostics, aimed not only at treating disease but also preventing disease, starting with asthma.

Talk to me about…something people may not know about you

My two professional passions have always been environmental systems and health. I have spent the entirety of my career exploring the relationship between these two concepts, from my time in the Solomon Islands as a Peace Corps Volunteer to my PhD work in marine ecosystems impacted by environmental alterations.

 

Bernat Olle

Co-founder and CEO
Vedanta Biosciences

In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management.

Bernat Olle

Co-founder and CEO
Vedanta Biosciences

Bernat Olle

Co-founder and CEO
Vedanta Biosciences

In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

 

Diwakar Davar

Assistant Professor
University of Pittsburgh, School of Medicine

Diwakar Davar

Assistant Professor
University of Pittsburgh, School of Medicine

Diwakar Davar

Assistant Professor
University of Pittsburgh, School of Medicine
 

Anne Marie Conway

VP of Clinical Operations
Finch Therapeutics

Anne Marie Conway is the VP of Clinical Operations at Finch Therapeutics. Anne Marie has over 30 years of clinical development experience in rare diseases (enzyme replacement and gene & cell therapies) along with academic nursing research experience in gastroenterology, neurology, and oncology.

Anne Marie Conway

VP of Clinical Operations
Finch Therapeutics

Anne Marie Conway

VP of Clinical Operations
Finch Therapeutics

Anne Marie Conway is the VP of Clinical Operations at Finch Therapeutics. Anne Marie has over 30 years of clinical development experience in rare diseases (enzyme replacement and gene & cell therapies) along with academic nursing research experience in gastroenterology, neurology, and oncology.

Prior to joining Finch, Anne Marie was Clinical Head of Biologics at PTC Therapeutics where she led the clinical development team for AGIL-AADC gene therapy leading to an MAA submission.
Prior PTC, Anne Marie was VP of Clinical Operations at Agilis Biotherapeutics responsible for clinical development operations and pharmacovigilance.

Before joining Agilis, Anne Marie founded AMC Consulting, LLC which provided clinical development support to companies.
Anne Marie also worked at Shire Human Genetic Therapies (HGT) and Transkaryotic Therapies (TKT) where she held increasingly senior leadership roles including VP of Clinical Development Operations. At HGT, she managed cross-functional teams that submitted four biologic license/new drug application filings with subsequent approvals.

Prior to joining TKT, she worked at Tufts Medical Center where she served as the Clinical Trials Manager for the Division of Gastroenterology and as a staff nurse.

Anne Marie is a Lecturer at Suffolk University’s Sawyer Business School teaching a graduate course on Healthcare Innovation.

Anne Marie holds a BS in Nursing from Boston University and a Master’s in Healthcare Administration from Suffolk University.

 

Colleen Cutcliffe

CEO and Co-Founder
Pendulum Therapeutics

Colleen Cutcliffe is a Biochemist and Molecular Biologist with 10 years of experience managing and directing fundamental biology research teams in the academic, pharmaceutical and biotech sectors. Prior to co-founding Pendulum Therapeutics, Colleen served as the Senior Manager of Biology at Pacific Biosciences where she met and collaborated with her fellow co-founders, John and Jim. Before her role at Pacific Biosciences, Colleen served as a Scientist in the Parkinson's Disease discovery group at Elan Pharmaceuticals.

Colleen Cutcliffe

CEO and Co-Founder
Pendulum Therapeutics

Colleen Cutcliffe

CEO and Co-Founder
Pendulum Therapeutics

Colleen Cutcliffe is a Biochemist and Molecular Biologist with 10 years of experience managing and directing fundamental biology research teams in the academic, pharmaceutical and biotech sectors. Prior to co-founding Pendulum Therapeutics, Colleen served as the Senior Manager of Biology at Pacific Biosciences where she met and collaborated with her fellow co-founders, John and Jim. Before her role at Pacific Biosciences, Colleen served as a Scientist in the Parkinson's Disease discovery group at Elan Pharmaceuticals. Colleen completed her postdoctoral research under Elizabeth Perlman at Children's Memorial Hospital in Chicago, IL, her Ph.D in Biochemistry and Molecular Biology under Cecile Pickart at Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.

 

Erik Pierstorff

Program Director
NSF

Erik Pierstorff joined the NSF as Program Director in November 2019. Prior to NSF, he was Chief of Operations and led Research and Development at O-Ray Pharma, where he focused on integrating biology and biomedical engineering for the goal of drug development and sustained drug delivery for the treatment of hearing loss and other ear disorders.

Erik Pierstorff

Program Director
NSF

Erik Pierstorff

Program Director
NSF

Erik Pierstorff joined the NSF as Program Director in November 2019. Prior to NSF, he was Chief of Operations and led Research and Development at O-Ray Pharma, where he focused on integrating biology and biomedical engineering for the goal of drug development and sustained drug delivery for the treatment of hearing loss and other ear disorders. During his time working at early-stage companies, he helped secure both Angel investment and non-dilutive funding in the form of licensing and co-development deals. Additionally, he served as Principal Investigator on several Phase I, II, and IIB SBIR grants from the National Institutes of Health and NSF. His research interests have focused on the intersection of the biotic and abiotic, spanning molecular and cell biology, materials science, gene therapy, nanomaterials, and drug delivery. Erik has a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and a B.S. in Biology from Emory University.

 

Gokul Swaminathan

Principal Scientist
Merck

Gokul Swaminathan

Principal Scientist
Merck

Gokul Swaminathan

Principal Scientist
Merck
 

James B. Adams

Director of the Autism/ Aspergers Research Program
Arizona State University

James B. Adams, Ph.D., is the Director of the Autism/Asperger's Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it including the areas of nutrition (vitamins/minerals, essential fatty acids, carnitine, digestive enzymes, special diets), oxidative stress, gut problems, gut bacteria, toxic metals, and seizures. He has published over 150 peer-reviewed scientific articles, including over 50 related to autism.

James B. Adams

Director of the Autism/ Aspergers Research Program
Arizona State University

James B. Adams

Director of the Autism/ Aspergers Research Program
Arizona State University

James B. Adams, Ph.D., is the Director of the Autism/Asperger's Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it including the areas of nutrition (vitamins/minerals, essential fatty acids, carnitine, digestive enzymes, special diets), oxidative stress, gut problems, gut bacteria, toxic metals, and seizures. He has published over 150 peer-reviewed scientific articles, including over 50 related to autism. He is also the President of the Autism Society of Greater Phoenix, the President of the Autism Nutrition Research Center, the co-leader of the Scientific Advisory Committee of the Autism Research Institute, and chair of the Scientific Advisory Board of the Neurological Health Foundation. He has an adult daughter with autism.

 

Jonathan Solomon

CEO
BiomX

Jonathan Solomon

CEO
BiomX

Jonathan Solomon

CEO
BiomX
 

Joseph Maxwell

Associate Director of Translational Research and Biomarkers
Takeda

Dr. Maxwell trained as an immunologist at Oregon State University and the University of Connecticut Health Center. He spent 15 years supporting early target discovery and program leadership at Amgen, AbbVie, and Finch Therapeutics with an emphasis in inflammatory bowel disease. He is currently an Associate Director of Translational Research and Biomarkers at Takeda supporting clinical programs testing microbiome therapies and other novel modalities in IBD and celiac disease.

Joseph Maxwell

Associate Director of Translational Research and Biomarkers
Takeda

Joseph Maxwell

Associate Director of Translational Research and Biomarkers
Takeda

Dr. Maxwell trained as an immunologist at Oregon State University and the University of Connecticut Health Center. He spent 15 years supporting early target discovery and program leadership at Amgen, AbbVie, and Finch Therapeutics with an emphasis in inflammatory bowel disease. He is currently an Associate Director of Translational Research and Biomarkers at Takeda supporting clinical programs testing microbiome therapies and other novel modalities in IBD and celiac disease.

 

Karen Kuphal

Head of Regulatory Affairs
Rebiotix

Karen E. Kuphal, Ph.D., MBA, PMP, has over 20 years of experience in advancing drug candidates within areas of rare disease and oncology. She is the Head of Regulatory Affairs at Rebiotix Inc, a Ferring Company, where she leads the team in advancing ground-breaking microbiota-based therapeutics. Prior to joining Rebiotix, Karen led the Oncology Regulatory Science and Strategy at AstraZeneca, where she played a major role in AstraZeneca’s first success in FDA’s Real-Time Oncology Review (RTOR) and “Orbis” programs, evidenced by the approval of Calquence within 2-months from submission.

Karen Kuphal

Head of Regulatory Affairs
Rebiotix

Karen Kuphal

Head of Regulatory Affairs
Rebiotix

Karen E. Kuphal, Ph.D., MBA, PMP, has over 20 years of experience in advancing drug candidates within areas of rare disease and oncology. She is the Head of Regulatory Affairs at Rebiotix Inc, a Ferring Company, where she leads the team in advancing ground-breaking microbiota-based therapeutics. Prior to joining Rebiotix, Karen led the Oncology Regulatory Science and Strategy at AstraZeneca, where she played a major role in AstraZeneca’s first success in FDA’s Real-Time Oncology Review (RTOR) and “Orbis” programs, evidenced by the approval of Calquence within 2-months from submission. She also served as a Portfolio Manager within Biologics Development at Bristol-Myers Squibb (BMS). Karen has held leadership positions at Cote Orphan Consulting (a boutique regulatory consulting service for orphan-based products), Sigma-Tau Pharmaceuticals (now Leadiant Biosciences), and Cardinal Health Specialty (Regulatory) Services.
Karen obtained her MBA from The George Washington University, with an emphasis in business analytics, and currently holds a PMP certification from the Project Management Institute. She completed her Ph.D. from the University of Kansas in Exercise Physiology, with post-doctoral training at the University of Missouri-Kansas City in Pharmacology.

 

Matt Henn

Executive Vice President & Chief Scientific Officer
Seres Therapeutics

Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres Therapeutics. He has over 20 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications.

Matt Henn

Executive Vice President & Chief Scientific Officer
Seres Therapeutics

Matt Henn

Executive Vice President & Chief Scientific Officer
Seres Therapeutics

Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres Therapeutics. He has over 20 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools to study microbial systems. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals. He currently serves on the scientific advisory board of Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in ecology and evolutionary sciences from the University of New Hampshire and his Ph.D. from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as an NSF Postdoctoral Fellow at Duke University.

 

Michal Daniely

Head of Microbiome Initiative
Merck Group

Michal is the Director of the Microbiome Initiative within Merck KGaA. In this role, she is responsible for developing technologies and products to advance microbiome research. Over the past 4 years, Michal has been deeply involved in shaping the company’s strategy within the microbiome research field to support the growing need in this market. The company is using core technologies such as microbial fermentation, Next Generation Sequencing (NGS), Mass Spectrometry (MS) for metabolomics & proteomics and more, to develop tools for microbiome researchers around the globe.

Michal Daniely

Head of Microbiome Initiative
Merck Group

Michal Daniely

Head of Microbiome Initiative
Merck Group

Michal is the Director of the Microbiome Initiative within Merck KGaA. In this role, she is responsible for developing technologies and products to advance microbiome research. Over the past 4 years, Michal has been deeply involved in shaping the company’s strategy within the microbiome research field to support the growing need in this market. The company is using core technologies such as microbial fermentation, Next Generation Sequencing (NGS), Mass Spectrometry (MS) for metabolomics & proteomics and more, to develop tools for microbiome researchers around the globe. Michal earned her Ph.D. degree in Human Genetics from the Sackler Medical School, Tel Aviv University, Israel. She is the author of many peer-review papers and is bringing significant scientific experience. Prior to joining Merck KGaA, she held different roles in medical device and pharma companies, where she managed the R&D activities. 

 

Sonia Timberlake

Senior Vice President of Research
Finch Therapeutics

Sonia is the Senior Vice President of Research at Finch Therapeutics. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.

Sonia Timberlake

Senior Vice President of Research
Finch Therapeutics

Sonia Timberlake

Senior Vice President of Research
Finch Therapeutics

Sonia is the Senior Vice President of Research at Finch Therapeutics. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology.

Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT.

 

Wayne Finlayson

Executive Director & CEO Servatus
Servatus

Wayne has extensive scientific and commercial corporate experience from over 35years in the pharmaceutical and biotechnology sector. Knowledge in regulatory structures and requirements, and experience in the commercialization of biotechnology, and the practical application of science for the creation of commercial enterprises. 

Wayne Finlayson

Executive Director & CEO Servatus
Servatus

Wayne Finlayson

Executive Director & CEO Servatus
Servatus

Wayne has extensive scientific and commercial corporate experience from over 35years in the pharmaceutical and biotechnology sector. Knowledge in regulatory structures and requirements, and experience in the commercialization of biotechnology, and the practical application of science for the creation of commercial enterprises. 

Wayne spent his early career years as a post-doctoral research fellow at the University of California, Berkley, following completion of a Ph.D. in Organic Chemistry from La Trobe University. He progressed from initial roles focusing on pure scientific research to more managerial positions in the science and technology sector, including executive director of Both (NASDAQ)and ASX listed companies. 

Wayne founded Progen Pharmaceuticals in the early 1990s and was managing director and CEO. After his time at Progen Pharmaceuticals, he worked as a technology investment consultant for high-profile clients (including large investment firms) with responsibility for ensuring the readiness of investee companies for public listing or other investment. 

Wayne’s experience, spanning the entire breadth of the biotechnology business spectrum, from a post-doctoral researcher to company founder and CEO, to investment consultant in the Biotechnology sector, means he has a thorough and well-rounded understanding of the challenges and expectations which need to be met to create and successfully commercialize biotechnological and pharmaceutical enterprises. 

 

Steward Campbell

CEO
Axial Therapeutics

Dr. Campbell joined Axial in 2016 as Vice President of Research & Development and was appointed the company’s CEO in February 2021.

In 27+ years in the pharma/biotech industry, Dr. Campbell held various leadership roles at Boehringer-Ingelheim, Insmed, Surface Logix, Ancora/Corden Pharma, and Axial.

Dr. Campbell has played an integral role in the discovery and development of eight clinical-stage drug candidates, including the Rho kinase inhibitor belumosudil and TAK-607 (rIGF-1/BP-3).

Steward Campbell

CEO
Axial Therapeutics

Steward Campbell

CEO
Axial Therapeutics

Dr. Campbell joined Axial in 2016 as Vice President of Research & Development and was appointed the company’s CEO in February 2021.

In 27+ years in the pharma/biotech industry, Dr. Campbell held various leadership roles at Boehringer-Ingelheim, Insmed, Surface Logix, Ancora/Corden Pharma, and Axial.

Dr. Campbell has played an integral role in the discovery and development of eight clinical-stage drug candidates, including the Rho kinase inhibitor belumosudil and TAK-607 (rIGF-1/BP-3).

During his career, Dr. Campbell has been co-inventor on 20 issued patents. He holds a BSc with Honors in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University (Canada), and did post-doctoral research at Duke University.

 

Federico Bolognani

VP & Head of Clinical Science
Axial Therapeutics

Dr. Bolognani joined Axial Therapeutics in November 2020, bringing with him over 20 years of experience in translational neuroscience research in academia, pharmaceutical, and the biotechnology industries.

Most recently, Federico served as the Vice President and Head of Clinical Science at VectivBio in Basel, Switzerland.

Prior to VectivBio AG, Dr. Bolognani was VP and Head of Clinical Science at Therachon AG, which was acquired by Pfizer in 2019.

Federico Bolognani

VP & Head of Clinical Science
Axial Therapeutics

Federico Bolognani

VP & Head of Clinical Science
Axial Therapeutics

Dr. Bolognani joined Axial Therapeutics in November 2020, bringing with him over 20 years of experience in translational neuroscience research in academia, pharmaceutical, and the biotechnology industries.

Most recently, Federico served as the Vice President and Head of Clinical Science at VectivBio in Basel, Switzerland.

Prior to VectivBio AG, Dr. Bolognani was VP and Head of Clinical Science at Therachon AG, which was acquired by Pfizer in 2019.

Prior to Therachon, Dr. Bolognani held various senior-level positions at Roche. As Translation Medicine Leader, Dr. Bolognani led several of Roche’s programs in neuroscience, including the successful Phase 2 balovaptan program in autism spectrum disorder, which was granted Breakthrough Designation in 2018.

Dr. Bolognani received his Ph.D. and M.D. from Universidad Nacional de La Pata, Argentina, and has an extensive scientific publication record in translational neuroscience research.

 

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America.

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America. Grégory also has experience managing IP, business development and general management.  He is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he has driven the development of several pharmaceutical products from the laboratory through to market authorisation. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations, so far has raised over 10M€ in a mixture of grant and VC funding and begins human clinical trials this year.

 

Ken Blount

Director
Rebiotix

Ken Blount, Ph.D., is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. 

Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center.

Ken Blount

Director
Rebiotix

Ken Blount

Director
Rebiotix

Ken Blount, Ph.D., is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. 

Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center.

Previously, he was a co-founder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech, that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections.

Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a Ph.D. in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

 

Magali Cordaillat-Simmons

Scientific and Regulatory Affairs Director
Pharmabiotic Research Institute (PRI)

Magali Cordaillat-Simmons earned her PhD in 2005 at Université Descartes - Paris, France, in Cardiovascular Pharmacology. She then worked as a Research Associate at the University of Virginia, USA, where she studied the influence of epigenetics on renin expression.

Today, she is the Scientific & Regulatory Affairs Director at the Pharmabiotic Research Institute (PRI), located in France.

Magali Cordaillat-Simmons

Scientific and Regulatory Affairs Director
Pharmabiotic Research Institute (PRI)

Magali Cordaillat-Simmons

Scientific and Regulatory Affairs Director
Pharmabiotic Research Institute (PRI)

Magali Cordaillat-Simmons earned her PhD in 2005 at Université Descartes - Paris, France, in Cardiovascular Pharmacology. She then worked as a Research Associate at the University of Virginia, USA, where she studied the influence of epigenetics on renin expression.

Today, she is the Scientific & Regulatory Affairs Director at the Pharmabiotic Research Institute (PRI), located in France.

The PRI is Europe’s first and only expert regulatory group dedicated to supporting its members in the development and market authorization of Microbiotic Medicinal Products (MMPs). As a non-profit, Pro-industry organization, the PRI is uniquely positioned to both be a trusted point of contact for the European regulatory authorities, as well as an agile and neutral partner for the Microbiome/Health industries.

Dr. Cordaillat-Simmons currently supervises the Association’s analysis of the European Pharmaceutical Legislation as well as the PRI’s regulatory intelligence strategy so that “Microbiotic Medicinal Products” become a therapeutic reality for European patients.

 

Rosa Krajmalnik-Brown

Director
Biodesign Center for Health Through Microbiomes

Dr. Rosa Krajmalnik-Brown is the director of the Biodesign Center for Health Through Microbiomes and a Professor at the School of Sustainable Engineering and The Built Environment, at Arizona State University.

She has a Ph.D. in Environmental Engineering from Georgia Tech. She was awarded an NSF CAREER award, was selected Fulton Engineering Exemplar Faculty and was recently awarded Arizona Researcher of the year by AZBio highly cited researcher in her field by Web of Science.

Rosa Krajmalnik-Brown

Director
Biodesign Center for Health Through Microbiomes

Rosa Krajmalnik-Brown

Director
Biodesign Center for Health Through Microbiomes

Dr. Rosa Krajmalnik-Brown is the director of the Biodesign Center for Health Through Microbiomes and a Professor at the School of Sustainable Engineering and The Built Environment, at Arizona State University.

She has a Ph.D. in Environmental Engineering from Georgia Tech. She was awarded an NSF CAREER award, was selected Fulton Engineering Exemplar Faculty and was recently awarded Arizona Researcher of the year by AZBio highly cited researcher in her field by Web of Science.

She has funding for her research from many federal agencies including NIH, DoE, DoD, and NSF. She is a pioneer in research on gut microbiome and autism.

She is the author of 4 patents and more than 115 peer-reviewed publications. She specializes in molecular microbial ecology for bioremediation, the use of microbial systems for bioenergy production, and the human intestinal microbial ecology and its relationship to obesity, bariatric surgery, metabolism, and autism.

 

Scott Jackson

Group Leader, Complex Microbial Systems
National Institute of Standards and Technology

Talk to me about… your research

Scott Jackson

Group Leader, Complex Microbial Systems
National Institute of Standards and Technology

Scott Jackson

Group Leader, Complex Microbial Systems
National Institute of Standards and Technology

Talk to me about… your research

I am the the leader of the Complex Microbial Systems Group at the National Institute of Standards and Technology (NIST) in Gaithersburg, MD. My current role involves leading international efforts to improve microbiome and metagenomic measurements by organizing inter-lab studies, developing reference materials and reference methods, and developing in vitro tools that allow us to better understand microbial community resilience and evolution Prior to joining NIST in 2014, I spent 11 years as a principal investigator with the FDA where I focused on characterizing the global genomic diversity of enteric pathogens, with applications for food safety, bioforensics and public health.

 

Christopher Missling

Anavex

Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp and has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work was dedicated to finding potential cures for neurodegenerative and neurodevelopmental diseases, like Alzheimer’s disease, and Parkinson’s disease, as well as Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms. Dr.

Christopher Missling

Anavex

Christopher Missling

Anavex

Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp and has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work was dedicated to finding potential cures for neurodegenerative and neurodevelopmental diseases, like Alzheimer’s disease, and Parkinson’s disease, as well as Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.

 

Christopher Carite

Development Director
4D Pharma

Christophe is a French citizen who graduated in industrial pharmacy (PharmD), Microbiology, and Business Administration.

He has started his industrial career as plant manager for Lallemand Bacteria Division early nineties, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients.

Christopher Carite

Development Director
4D Pharma

Christopher Carite

Development Director
4D Pharma

Christophe is a French citizen who graduated in industrial pharmacy (PharmD), Microbiology, and Business Administration.

He has started his industrial career as plant manager for Lallemand Bacteria Division early nineties, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients.

He has joined 4D pharma at the early beginning of the company in 2014 and he has undertaken the challenge to produce freeze-dried strict anaerobic bacteria at the industrial scale level ( 3500 L fermentor, 5 to 20m2 Freeze dryer) to deliver high concentrated LBPs to patients (> 1010 CFU/caps, shelf life up to 2 years) recognised by several patent families granted. In addition, Christophe has integrated “in-house” all 4D pharma Manufacturing and Controls under inspected cGMP.
Right now, he assumes the position of Process development/CMC Director and member of the 4D Pharma Executive team reporting directly to the CEO.

 

Dirk Gevers

Global Head
Janssen Human Microbiome Institute

Dirk Gevers, Ph.D., is Global Head of the Microbiome Solutions team. As a team, we combine our pioneering expertise in the microbiome with the drug discovery, product development, and commercialization know-how of a leading global healthcare company. Together with our colleagues across Janssen and Johnson & Johnson, we have the knowledge and resources to identify the most promising innovations taking place across the microbiome ecosystem and help our partners translate early-stage innovations into product concepts and, ultimately, new solutions with the power to impact human health.

Dirk Gevers

Global Head
Janssen Human Microbiome Institute

Dirk Gevers

Global Head
Janssen Human Microbiome Institute

Dirk Gevers, Ph.D., is Global Head of the Microbiome Solutions team. As a team, we combine our pioneering expertise in the microbiome with the drug discovery, product development, and commercialization know-how of a leading global healthcare company. Together with our colleagues across Janssen and Johnson & Johnson, we have the knowledge and resources to identify the most promising innovations taking place across the microbiome ecosystem and help our partners translate early-stage innovations into product concepts and, ultimately, new solutions with the power to impact human health.


Dirk joined from his previous role as Senior Group Leader of Microbial Systems and Communities at the Broad Institute of MIT and Harvard. In this position, Dirk served as a scientific liaison between different organizational components, including the Broad Institute’s data generation platforms and both clinical and analytical collaborators on a number of microbiome-related projects. Dirk’s research efforts at the Broad Institute included the characterization of the microbial imbalance associated with diseases such as Crohn’s disease, type 1 diabetes, and colorectal cancer. He was also involved with the National Institutes of Health (NIH) Human Microbiome Project (HMP), holding a leading role in the Data Analysis Working Group, consisting of over 50 investigators focused on human microbiome research.


Dirk received his Ph.D. in biochemistry from Ghent University (UGent), Belgium, and completed postdoctoral training at UGent and Massachusetts Institute of Technology (MIT) in bioinformatics, comparative and evolutionary genome analysis, and microbial ecology.

 

Staffan Stromberg

CEO
Infant Bacterial Therapeutics

Staffan Stromberg

CEO
Infant Bacterial Therapeutics

Staffan Stromberg

CEO
Infant Bacterial Therapeutics
 

Aaron Anselmo

Assistant Professor
The University of North Carolina at Chapel Hill

Aaron Anselmo

Assistant Professor
The University of North Carolina at Chapel Hill

Aaron Anselmo

Assistant Professor
The University of North Carolina at Chapel Hill
 

Anita Patel Jusnes

Chief Commercial Officer
Genetic Analysis

Anita Patel Jusnes

Chief Commercial Officer
Genetic Analysis

Anita Patel Jusnes

Chief Commercial Officer
Genetic Analysis
 

Carole Schwintner

Chief Technical Officer
MaaT Pharma

Carole Schwintner

Chief Technical Officer
MaaT Pharma

Carole Schwintner

Chief Technical Officer
MaaT Pharma
 

Denise Kelly

Investment Advisor
Seventure

Denise Kelly

Investment Advisor
Seventure

Denise Kelly

Investment Advisor
Seventure
 

John Weinberg

Chief Medical Officer
MaaT Pharma

John Weinberg

Chief Medical Officer
MaaT Pharma

John Weinberg

Chief Medical Officer
MaaT Pharma
 

Rochellys Diaz Heijtz

Associate Professor
Karolinska Institute

Rochellys Diaz Heijtz

Associate Professor
Karolinska Institute

Rochellys Diaz Heijtz

Associate Professor
Karolinska Institute
 

Romaine Daillere

Co-Founder & Head of Preclinical Research
EVERIMMUNE

Romaine Daillere

Co-Founder & Head of Preclinical Research
EVERIMMUNE

Romaine Daillere

Co-Founder & Head of Preclinical Research
EVERIMMUNE
 

Ruth Luna Ann

Assistant Professor
Baylor College of Medicine

Ruth Luna Ann

Assistant Professor
Baylor College of Medicine

Ruth Luna Ann

Assistant Professor
Baylor College of Medicine
 

Henrik Bjørn Nielsen

CEO
Clinical Microbiomics

Henrik Bjørn Nielsen

CEO
Clinical Microbiomics

Henrik Bjørn Nielsen

CEO
Clinical Microbiomics

2021 ATTENDEES

Microbiome Connect Gut Therapeutics Boston 2021 Kisaco Research

Testimonials

Microbiome Connect Gut Therapeutics Boston 2021 Kisaco Research

Submit your poster

Are you looking to showcase your recent work to the microbiome community?

Our dedicated poster session is the perfect way to get your research noticed. To present a poster, you need to register as a delegate. Please note that there is limited space available, and poster space is assigned on a first-come, first-served basis (subject to checks and successful registration). At the event, your presentation will be displayed in a dedicated poster area. The poster presentation session time of taking place is to be confirmed.

The poster abstract submission deadline is on 28th September 2021.

Abstracts received after this time may not be accepted, so please submit your abstract as soon as possible!

Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

If you have any questions, please contact [email protected]

CLICK HERE TO MAKE A SUBMISSION

#McGut

#McGut: 

Sponsors

Platinum Event Partner

Gold Event Partner

Silver Event Partner

Event Partner

Media Partners

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Super Early Bird Ends In

Tuesday, July 6, 2021 to Friday, August 27, 2021
Academics and Research Institutions
$699
Super Early Bird rate until August 27 (Standard £1299)
2 Day In-Person Conference Pass
In-Person networking opportunities
Access to Microbiome Connect: Skin & Oral; hosted on same date & location
Tuesday, July 6, 2021 to Friday, August 27, 2021
Big Pharma and Biotechnology Companies
$1499
Super Early Bird rate until August 27 (Standard £1999)
2 Day In-Person Conference Pass
In-Person networking opportunities
Access to Microbiome Connect: Skin & Oral; hosted on same date & location
Tuesday, July 6, 2021 to Friday, August 27, 2021
Service Providers & Industry
$1999
Super Early Bird rate until August 27 (Standard £3099)
2 Day In-Person Conference Pass
In-Person networking opportunities
Access to Microbiome Connect: Skin & Oral; hosted on same date & location
Preparing registration...

Resources

Download Resource

Venue

275 Tremont St, Boston, MA 02116, United States

Join the Microbiome Connect community at the picturesque Courtyard by Marriott, Boston, Downtown Boutique Hotel.

Bedrooms: $239 + tax per room per night

Please call Marriott reservations at 1 (800) 321-2211 or (617) 426-1400 and quote Kisaco Research/Microbiome.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Other events you might be interested in:

Microbiome Oral USA